[1] Surveillance Epidemiology, and End Results Program. Introduction to Breast Cancer. https://www.training.seer.cancer.gov/breast/intro/. Accessed 9 July 2019.
[2] Kimbung S, Loman N, Hedenfalk I. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 2015, 35: 85-95.
[3] Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011, 129(2): 495-503.
[4] Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, Amelio J. Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol. 2017, 115: 67-80.
[5] Desantis CE, Fedewa SA, Goding SA, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016, 66(1): 31-42.
[6] Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer. 2000, 36(4): 476-482.
[7] Yavas O, Hayran M, Ozisik Y. Factors affecting survival in breast cancer patients following bone metastasis. Tumori. 2007, 93(6): 580-586.
[8] Ahn SG, Lee HM, Cho SH, Lee SA, Hwang SH, Jeong J, Lee HD. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J. 2013, 54(5): 1168-1177.
[9] Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep. 2017, 7: 45411.
[10] Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98(19): 10869-10874.
[11] Koenders PG, Beex LV, Langens R, Kloppenborg PW, Smals AG, Benraad TJ. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res Treat. 1991, 18(1): 27-32.
[12] Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn, JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68(9): 3108-3114.
[13] Tobin NP, Harrell JC, Lovrot J, Egyhazi BrageS, Frostvik StoltM, Carlsson L, Einbeigi Z, Linderholm B, Loman N, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol. 2015, 26(1): 81-88.
[14] Li BT, Wong MH, Pavlakis N. Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. J Clin Med. 2014, 3(1): 1-24.
[15] Surveillance, Epidemiology, and End Results Program. Data use agreement for the 1975-2016 SEER Research Data File. https://seer.cancer.gov/data/sample-dua.html .Accessed 12 July 2019.
[16] Diessner J, Wischnewsky M, Stuber T, Stein R, Krockenberger M, Hausler S, Janni W, Kreienberg R, Blettner M,Schwentner L. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer. BMC Cancer. 2016, 16: 307.
[17] Leone BA, Vallejo CT, Romero AO, Machiavelli MR, Perez JE, Leone J, Leone, J P. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis. Breast Cancer Res Treat. 2017, 161(3): 537-548.
[18] Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GN. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer. 2018, 4: 2.
[19] Press DJ, Miller ME, Liederbach E, Yao K, Huo D. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis. 2017, 34(8): 457-465.
[20] Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M. Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre. J Bone Oncol. 2013, 2(4): 137-144.
[21] Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw A J, Peters FP, van Riel JM, Peters NA,et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?. Br J Cancer. 2015, 112(9): 1445-1451.
[22] Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010, 28(1): 92-98.
[23] Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 2010, 28(11): 1813-1820.
[24] Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295(21): 2492-2502.
[25] Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi-Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris J R. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008, 26(14): 2373-2378.
[26] Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Toyozumi Y, Arima N. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol. 2014, 2(6): 1062-1068.
[27] Gnant M, Harbeck N, Thomssen C. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care (Basel). 2017, 12(2): 102-107.
[28] Cronin-Fenton D, Kjærsgaard A, Nørgaard M, Amelio J, Liede, A, Hernandez RK, Sorensen HT. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat, 167(2): 517-528.
[29] Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States. JAMA. 2015;313(2):165–173. doi:10.1001/jama.2014.17322.
[30] Rendall MS, Weden MM, Favreault MM, Waldron H. The protective effect of marriage for survival: a review and update. Demography, 2011. 48(2): p. 481-506.